Healthequity, INC Form 4 insider transactions

HealthEquity's EVP, Chief Commercial Officer, Michael Henry Fiore, reported the sale of 1,781 shares of common stock and disposition of 1,649 shares for tax withholding purposes.

HealthEquity's Chief Technology Officer, Elimelech Rosner, disposed of 3,006 shares of common stock to cover tax withholding obligations at a price of $88.5674 per share.

HealthEquity's EVP, General Counsel, Delano Ladd, sold 6,000 shares of common stock on September 19, 2025, through a pre-arranged 10b5-1 trading plan.

HealthEquity Director Evelyn Dilsaver exercised stock options and subsequently sold a portion of the acquired shares.

HEALTHEQUITY, INC. Founder and Vice Chairman Stephen Neeleman reported a future disposition of 3,000 common shares via gift, scheduled for July 28, 2025, under a Rule 10b5-1 plan.

HealthEquity's EVP and General Counsel, Delano Ladd, disposed of 970 shares of common stock on July 3, 2025, to satisfy tax withholding obligations at a price of $100.8721 per share.

HealthEquity's EVP & CFO, James M. Lucania, reported a future disposition of 2,375 shares of common stock on July 3, 2025, at a price of $100.8721 per share, primarily for tax withholding.

Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., reported the disposition of 1,049 shares of common stock to cover tax withholding obligations at a price of $100.8721 per share.

HealthEquity's EVP and Chief Technology Officer, Elimelech Rosner, reported a disposition of 2,982 shares of common stock to cover tax withholding obligations at a price of $100.8721 per share.

HealthEquity's EVP, Chief Commercial Officer, Michael Henry Fiore, reported the disposition of 1,636 shares for tax withholding and the sale of 1,794 common shares, all executed under a Rule 10b5-1 trading plan.

HealthEquity, Inc. Director Evelyn S. Dilsaver reported the acquisition of 2,003 restricted stock units and detailed her existing stock option holdings, pursuant to a Rule 10b5-1 plan.

HealthEquity, Inc. Director Robert W. Selander has acquired 2,003 restricted stock units, increasing his direct beneficial ownership to 86,972 shares.

HealthEquity, Inc. Director Adrian T. Dillon acquired 2,003 shares of common stock through a restricted stock unit grant, increasing his total beneficial ownership to 59,518 shares.

HealthEquity, Inc. Director Gayle Furgurson Wellborn acquired 2,003 shares of common stock through restricted stock units, increasing her direct beneficial ownership to 19,733 shares.

HealthEquity, Inc. Director Debra McCowan acquired 2,003 shares of common stock through a restricted stock unit grant on June 26, 2025, increasing her total beneficial ownership to 9,782 shares.

HealthEquity, Inc. Director Rajesh Natarajan has acquired 2,003 restricted stock units, increasing his direct beneficial ownership to 14,277 shares of common stock.

HealthEquity, Inc. Director Stuart B. Parker was granted 2,003 restricted stock units, increasing his total beneficial ownership to 21,835 common shares.

Former HealthEquity, Inc. director Jon Kessler reported exercising stock options and subsequently selling a significant number of common shares, both directly and indirectly through GKF, LLC, on June 6, 2025.

HealthEquity's Executive Vice President and Chief Technology Officer, Elimelech Rosner, sold 71,000 shares of common stock for approximately $7.98 million in early June 2025, pursuant to a Rule 10b5-1 trading plan.

Robert W. Selander, a director at HealthEquity, Inc., executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., reported disposing of 9,019 shares of common stock on April 8, 2025, to cover tax obligations.

Delano Ladd, EVP and General Counsel of HealthEquity, Inc., reported the disposal of 6,991 shares of common stock on April 8, 2025.

Director Jon Kessler reports disposition of HealthEquity stock to cover tax obligations, while maintaining significant holdings.

Elimelech Rosner, EVP, CHIEF TECHNOLOGY OFFICER of HealthEquity, Inc., reports the disposal of 52,078 shares of common stock to cover tax obligations.

Michael Fiore, EVP and Chief Commercial Officer of HealthEquity, Inc., sold 8,881 shares of common stock at a price of $78.2621 per share on April 4, 2025, under a pre-arranged 10b5-1 trading plan.

Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., reports transactions involving common stock and restricted stock units, resulting in changes to his beneficial ownership.

Director Jon Kessler reports acquisition and disposal of HealthEquity, Inc. common stock and holdings of derivative securities.

EVP and Chief Commercial Officer of HealthEquity, Michael Fiore, reports acquisition and disposal of company stock.

EVP and Chief Technology Officer of HealthEquity, Elimelech Rosner, reports acquisition and disposal of common stock and restricted stock units.

James Lucania, EVP & CFO of HealthEquity, Inc., reported the acquisition and disposal of company stock on April 2nd and 3rd, 2025.